S4 Table. Antimicrobial susceptibility testing of the *C. difficile* R20291 wt and R20291-LexA::CT mutant

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Class** | **Symbol** | **Antibiotic** | **AST method** | **Antibiotic concentration**  **(µg/ml)** | **MIC breakpoint** | **Medium** | **MIC**  **(µg/ml)** | **MIC**  **(µg/ml)** |
|  |  |  | **R20291 wt** | **R20291-LexA::CT** |
| Protein  synthesis  inhibitors | EM | Erythromycin | Etest® | 0.016-256 | 8b | COS\* | >256 | >256 |
| TC | Tetracycline | Etest® | 0.016-256 | 8b | COS | 0,19 | 0,125 |
| DC | Doxycycline | Etest® | 0.016-256 | ND | COS | 0.032 | 0,047 |
|  | CM | Clindamycin  (LM derivate) | Etest® | 0.016-256 | 8b | COS | 1.5 | >256 |
| DNA/RNA  synthesis  inhibitors |  |  |  |  |  |  |  |  |
| LE | Levofloxacin | Etest® | 0.002-32 | 4-8d | COS | >32 | >32 |
| RI | Rifampicin | Etest® | 0.002-32 | 0.004a | COS | 0.003 | 0,003 |
|  | **MZ** | **Metronidazole** | Etest® | **0.016-256** | **2a** | **COS** | **1.5-2.0** | **0.5** |
|  |  |  |  |  |  |  |  |  |
| Cell wall  synthesis  inhibitors | VA | Vancomycin | Etest® | 0.016-256 | 2a | COS | 0.5 | 0.75 |
| PTc | Pipera/Tazo | Etest® | 0.016-256 | ND | COS | 12 | 8 |
| AC | Amoxicillin | Etest® | 0.016-256 | 16c | COS | 1.0 | 0,75 |
| AM | Ampicillin | AD | 0.125-32 | ND | BHIS | 8 | 4 |
| AM | Ampicillin | AD | 0.125-32 | ND | PY | 4 | 4 |

\*COS plates, BHIS broth, PY broth

AD – agar dilution

ND not defined by EUCAST

a ([EUCAST 2015](#_ENREF_1))

b ([Lachowicz D. *et al.,* 2015](#_ENREF_3))

c ([Keessen E. C. *et al.,* 2013](#_ENREF_2))

d ([Spigaglia P. *et al.,* 2008](#_ENREF_4))